[HTML][HTML] Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: focus on novel …
M Johnson, MC Garassino, T Mok, T Mitsudomi - Lung Cancer, 2022 - Elsevier
Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …
[HTML][HTML] Molecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapy
K Domvri, P Zarogoulidis, K Darwiche… - Journal of …, 2013 - ncbi.nlm.nih.gov
Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet
chemotherapy to the molecular targeted. The major limitation of the targeted therapies still …
chemotherapy to the molecular targeted. The major limitation of the targeted therapies still …
Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
IZ Uras, HP Moll, E Casanova - International Journal of Molecular …, 2020 - mdpi.com
Lung cancer is the most frequent cancer with an aggressive clinical course and high
mortality rates. Most cases are diagnosed at advanced stages when treatment options are …
mortality rates. Most cases are diagnosed at advanced stages when treatment options are …
[HTML][HTML] Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer
Lung cancer represents the leading cause of cancer-related deaths worldwide. Despite
great advances in its management with the recent emergence of molecular targeted …
great advances in its management with the recent emergence of molecular targeted …
Current landscape of targeted therapy in lung cancer
MK Mayekar, TG Bivona - Clinical Pharmacology & …, 2017 - Wiley Online Library
Lung cancer is the leading cause of cancer mortality worldwide. Comprehensive genomic
profiling of lung cancers revealed their genetic heterogeneity and complexity and identified …
profiling of lung cancers revealed their genetic heterogeneity and complexity and identified …
[HTML][HTML] Molecular pathology of lung cancer: key to personalized medicine
L Cheng, RE Alexander, GT MacLennan… - Modern Pathology, 2012 - Elsevier
The majority of lung adenocarcinoma patients with epidermal growth factor receptor-(EGFR)
mutated or EML4–ALK rearrangement-positive tumors are sensitive to tyrosine kinase …
mutated or EML4–ALK rearrangement-positive tumors are sensitive to tyrosine kinase …
[HTML][HTML] Recent advances in non-small cell lung cancer biology and clinical management
P Saintigny, JA Burger - Discovery medicine, 2012 - discoverymedicine.com
Despite advances in surgery, chemotherapy, and radiotherapy over the last decades, the
death rate from lung cancer has remained largely unchanged, which is mainly due to …
death rate from lung cancer has remained largely unchanged, which is mainly due to …
Tumor Clonality and Resistance Mechanisms in EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Implications for Therapeutic Sequencing
S Kohsaka, M Petronczki, F Solca… - Future Oncology, 2018 - Taylor & Francis
While the development of EGFR-targeted tyrosine kinase inhibitors (TKIs) has revolutionized
treatment of EGFR mutation-positive non-small-cell lung cancer, acquired resistance to …
treatment of EGFR mutation-positive non-small-cell lung cancer, acquired resistance to …
A RAS renaissance: emerging targeted therapies for KRAS-mutated non–small cell lung cancer
Of the numerous oncogenes implicated in human cancer, the most common and perhaps
the most elusive to target pharmacologically is RAS. Since the discovery of RAS in the …
the most elusive to target pharmacologically is RAS. Since the discovery of RAS in the …
Recent progress in targeted therapy for non-small cell lung cancer
Y Xiao, P Liu, J Wei, X Zhang, J Guo… - Frontiers in Pharmacology, 2023 - frontiersin.org
The high morbidity and mortality of non-small cell lung cancer (NSCLC) have always been
major threats to people's health. With the identification of carcinogenic drivers in non-small …
major threats to people's health. With the identification of carcinogenic drivers in non-small …